EXPLORE AREAS OF INTEREST
- Genomic Medicine
- Hereditary Cancer Risk Assessment
- Reproductive Medicine
- Hearing Loss & Newborn Screening
- Clinical Exome Sequencing
Otogenetics is a Next Generation Sequencing (NGS) laboratory service provider established by two professors from Emory University School of Medicine in 2007 with NIH funding. The company developed and launched a Newborn Screening Hearing Loss Panel sequencing 167 genes associated with Syndromic and Non-Syndromic Hearing Loss. Our test offering now includes Genomic Medicine, Hereditary Cancer Risk Assessment, Expanded Carrier Screening, Pharmacogenomics & Personalized Medicine, Cardiomyopathy, and Whole Exome & RNA Sequencing for precision treatment of tumors, and testing for Rare Diseases. Disease panels are custom designed for both research collaborators and clinical diagnostics.
Test results for genetic diagnoses and risk assessment using NGS technologies resulted in publications in highly reputable biomedical journals including Nature and Nature Medicine; attesting to the high caliber and quality of the gene panel design offered by the company. Otogenetics also assists medical schools in training a new generation of medical students in Precision Medicine.
Publications & Press Releases
Deep Exome Sequencing by Otogenetics for Clinical Researchers leads to discovery of key somatic mutations in MAP2K1 in melorheostotic* bones of patients. (*Melorheosis is characterized by excess bone formation on the surface of the bone. The bone overgrowth lesions are…
Otogenetics hearing loss gene test lend the tool for clinicians to discover an autosomal dominant hearing loss mutation in POU4F3 gene. This particular variant t cosegregated with hearing loss in family members but was not detected in 580 normal hearing…
US life expectancy varies > 20 years regionally. Access to quality healthcare, such as early cancer screening, is a contributing factor. Check out the new study published in JAMA Internal Medicine (May 8, 2017), and check out Gx™ cancer genetic screening.